- hello@nugenialogics.com
- San Diego, CA
Peptide Stacking, Organised by Pathway — Not by Goal
Most stacking guides group compounds by outcome: fat loss, muscle, recovery. That grouping hides the thing that actually matters — how many compounds in a stack act on the same biological pathway, and whether your own genotype makes that pathway the limiting factor at all.
A goal-based stack is assembled backwards. Someone picks an outcome, then collects the compounds most often associated with it. The result is usually three or four compounds converging on one mechanism — and nothing touching the pathway that was actually constraining the outcome.
A "recovery stack" that pairs BPC-157 with TB-500 is a reasonable example. Both are studied in tissue-repair contexts, and both are widely discussed for the same goal. But grouping them by goal tells you nothing about whether they act redundantly, complementarily, or on entirely separate limbs of repair — and nothing at all about why the same pairing is reported very differently by different people.
Pathway grouping answers a different question: what is this stack actually converging on, and is that convergence the point or the problem?
These are the pathways NuGenia's insight reports are built around. Each one has its own marker set, and each compound below is grouped by the pathway it is primarily studied in — not by the outcome it gets marketed for.
Growth Hormone & Tissue Repair
Secretagogue signalling and the repair cascade downstream of it. The most commonly over-stacked pathway, because several popular compounds converge here.
Inflammation & Immune Modulation
Cytokine signalling and immune tone. Frequently the pathway that actually gates a repair outcome, while the stack is aimed elsewhere.
Longevity & Cellular Aging
Telomere maintenance and senescence signalling. Long time-horizon, and the pathway least likely to show anything on a short observation window.
Cognitive Performance
BDNF signalling and neurotrophic response. Genotype variance here is unusually wide, which is why identical reports diverge so sharply.
Mood & Stress Resilience
Stress-axis regulation and anxiolytic signalling. Overlaps the cognitive pathway enough that stacking both often double-counts one mechanism.
Sleep & Recovery Regulation
Circadian and recovery signalling. Usually the pathway that silently limits everything stacked on top of it.
Muscle Hypertrophy
Myostatin and hypertrophic signalling. Distinct from the growth-hormone pathway, though stacks routinely treat the two as one.
Weight Management
Incretin signalling. The most mechanistically crowded pathway in current research, and the easiest to stack redundantly.
Energy Metabolism
AMPK and mitochondrial signalling. Two compounds here act on the same node, which makes it a clean illustration of redundancy.
Skin Health & Regeneration
Collagen turnover and dermal remodelling. Shares collagen machinery with tissue repair, so the two pathways are not independent.
Overlap is not automatically bad. Two compounds on one pathway can be complementary if they act at different points in it, and redundant if they act at the same point. The distinction is mechanistic, not a matter of how the stack is marketed.
| Common pairing | Pathways involved | What the overlap means |
|---|---|---|
| BPC-157 + TB-500 | Tissue Repair, Inflammation | Two pathways, not one. Studied at different points of the repair cascade, which is why it reads as complementary rather than duplicative. |
| MOTS-c + AICAR | Energy Metabolism | Single pathway, closely related nodes. The clearest case of convergence in this catalogue — more of the same signal, not a second lever. |
| Semax + Selank | Cognitive, Mood & Stress | Adjacent pathways with shared neurotrophic elements. Whether that is one mechanism or two depends heavily on individual marker profile. |
| Incretin compounds together | Weight Management | Single pathway, overlapping receptor targets. Convergence is the defining feature of this group rather than an incidental property. |
| GHK-Cu + repair compounds | Skin Health, Tissue Repair | Shared collagen machinery. The two pathways are not independent, so effects on one are not cleanly separable from the other. |
Why the same stack produces different reports
Two people running an identical combination frequently describe very different experiences, and the usual explanations — sourcing, purity, consistency — only account for part of it. The rest is genetic variance in the pathways the compounds act on.
A compound studied for its effect on a signalling pathway can only produce a measurable difference if that pathway is both responsive and relevant in the individual. Variants across the genes governing these pathways shift both. This is why pathway-level reasoning outperforms goal-level reasoning: the goal is the same for everyone, but the constraint is not.
Convergence versus complementarity
Two compounds on the same pathway may act at the same node or at different ones. Acting at the same node adds signal to a mechanism that may already be saturated. Acting at different nodes within the pathway is a different proposition. Neither is inherently preferable — but a stack assembled by goal cannot tell you which one you have built.
What pathway grouping does not tell you
Pathway mapping is a reasoning framework, not a protocol. It does not establish safety, does not indicate that any combination is appropriate for any person, and does not speak to quantity, timing, or administration. Those questions are outside what this page addresses and outside what NuGenia publishes.
Reading your own pathways
If you have run a consumer DNA test, the raw data file already contains the markers these pathways are scored on. NuGenia's insight reports read that file and return a pathway-level profile — which pathways carry variants worth knowing about, and which are unremarkable.
- Ten pathways, each with its own curated marker set
- Deterministic scoring — the same file returns the same result
- Works with 23andMe, AncestryDNA, MyHeritage and FamilyTreeDNA exports
Common questions
Pathway framing, and what it does and does not cover.